12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BT-062: Additional Phase I data

Additional data from 27 evaluable patients with relapsed and/or refractory MM in an ongoing, open-label, dose-escalation, U.S. Phase I trial showed that 10-200 mg/m 2 IV BT-062 produced 1 partial response, 2 minor responses and 11 cases of stable disease for...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >